Bausch + Lomb (NYSE:BLCO – Get Free Report) and NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.
Profitability
This table compares Bausch + Lomb and NeuroOne Medical Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bausch + Lomb | -4.21% | 3.60% | 1.69% |
| NeuroOne Medical Technologies | -68.35% | -98.33% | -69.85% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Bausch + Lomb and NeuroOne Medical Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bausch + Lomb | 1 | 9 | 4 | 0 | 2.21 |
| NeuroOne Medical Technologies | 1 | 1 | 3 | 0 | 2.40 |
Insider & Institutional Ownership
11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk and Volatility
Bausch + Lomb has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
Earnings and Valuation
This table compares Bausch + Lomb and NeuroOne Medical Technologies”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bausch + Lomb | $5.21 billion | 1.09 | -$360.00 million | ($0.62) | -25.73 |
| NeuroOne Medical Technologies | $12.10 million | 2.63 | -$3.61 million | ($0.85) | -4.34 |
NeuroOne Medical Technologies has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
NeuroOne Medical Technologies beats Bausch + Lomb on 8 of the 14 factors compared between the two stocks.
About Bausch + Lomb
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.
